Treatment of peanut allergy with tolerizing nanoparticles
AssigneeCour Pharmaceuticals Development Company, Inc.
InventorsJohn Puisis, James Herrmann, Michael Boyne, Adam Elhofy, Joseph Podojil, Greta Wodarcyk
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general to methods of treating peanut allergy using nanoparticles encapsulating peanut antigens to induce antigen-specific tolerance.
Claims48
A method of treating peanut allergy in a subject comprising administering to the subject tolerizing immune modifying particles encapsulating peanut proteins (TIMP-PPE), alone or in combination with one or more additional therapeutics, wherein TIMP-PPE is administered at a dose level of between about 0.1 mg/kg and 12 mg/kg.
The method of any one of the preceding claims, wherein the particles have a negative zeta potential of between −30 mV and −100 mV.
The method of any one of the preceding claims, wherein TIMP-PPE is administered at a concentration of between about 0.05 mg/mL and about 50 mg/mL, optionally about 0.1 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12.5 mg/mL, 15 mg/mL, 17.5 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL, 40 mg/mL, or 50 mg/mL.
The method of any one of the preceding claims, wherein TIMP-PPE is administered at a dose level of about 0.1 mg/kg, 0.25, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg, 6 mg/kg, 8.0 mg/kg, 10 mg/kg, or 12 mg/kg.
The method of any one of the preceding claims, wherein TIMP-PPE is administered at a dose level of between about 10 mg and 800 mg.
The method of any one of the preceding claims, wherein TIMP-PPE is administered at a dose of about 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, or 800 mg.
The method of any one of the preceding claims, wherein TIMP-PPE is administered in a single dose or in multiple doses.
The method of any one of the preceding claims, wherein TIMP-PPE is administered once weekly, once every two weeks, once every three weeks, once every 4 weeks, once every two months, once every three months, once every 6 months, or once per year.
The method of any one of the preceding claims, wherein TIMP-PPE is administered in two doses one-week apart.
The method of any one of the preceding claims, wherein TIMP-PPE is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, intranasally, or orally.
The method of any one of the preceding claims, wherein TIMP-PPE is administered at a concentration of between 0.05 mg/mL and 50 mg/mL.
The method of any one of the preceding claims, wherein the additional therapeutic inhibits IgE.
The method of any one of the preceding claims, wherein administering TIMP-PPE alone or in combination with an additional therapeutic to the subject reduces one or more symptoms of peanut allergy.
The method of any one of the preceding claims, wherein administering TIMP-PPE alone or in combination with an additional therapeutic to the subject reduces the duration and severity of the allergic immune response to peanut proteins.
The method of any one of the preceding claims, wherein administering TIMP-PPE alone or in combination with an additional therapeutic to the subject increases tolerance to peanut proteins.
The method of any one of the preceding claims, wherein the TIMP-PPE comprises a peanut extract or one or more peanut proteins or antigenic fragments thereof selected from the group consisting of Ara h1, Ara h2, Ara h3, Ara h5, Ara h6, Ara h7, Ara h8, Ara h9, Ara h10, Ara h11, Ara h12, Ara h13, Ara h14, Ara h15, Ara h16, Ara h17, and Ara h18.
The method of any one of the preceding claims, wherein the TIMP-PPE comprises one or more proteins or antigenic fragments thereof of Ara h1, Ara h2, Ara h3, Ara h5, Ara h6, Ara h7, or Ara h8.
The method of any one of the preceding claims, wherein the subject is administered an antihistamine and/or a corticosteroid prior to treatment with TIMP-PPE.
The method of claim 46 or 47, wherein the corticosteroid is methylprednisolone.
Dependencies are inferred from the claim text.